This inventor holds 1 USPTO granted patent and 5 published patent applications and 3 EPO patents. Top assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum. Active years: 2022.
Company Filing History:
1 out of 12,266 
1 out of 386 
1 out of 159 
Years Active: 2022
Title: Innovator Spotlight: Gabriele Leder - Revolutionizing Pharmaceuticals
Introduction:
Gabriele Leder, a pioneering inventor based in Berlin, DE, has made significant contributions to the field of pharmaceuticals with his groundbreaking patented invention.
Latest Patents:
Gabriele Leder holds a notable patent for Substituted Pyrrolopyridine-Derivatives, which focuses on protein-inhibitory compounds for the treatment of diseases such as neoplastic disorders, cancer, dysregulated immune responses, and other conditions associated with aberrant MAP4K1 signaling.
Career Highlights:
Throughout his career, Gabriele Leder has been associated with prestigious companies such as Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft, where he has played a crucial role in advancing pharmaceutical research and development.
Collaborations:
Gabriele Leder has collaborated closely with accomplished professionals in the field, including Jeffrey Stuart Mowat and Bernd Buchmann, to further enhance the efficacy and scope of his innovative pharmaceutical inventions.
Conclusion:
In conclusion, Gabriele Leder's inventive work in the realm of pharmaceuticals, particularly with his patented Substituted Pyrrolopyridine-Derivatives, showcases his dedication to advancing medical treatments and improving outcomes for patients worldwide.